Search Results

The Sensititre Haemophilus influenzae/Streptococcus pneumoniae plates are in vitro diagnostic products for clinical susceptibility testing of Haemophilus influenzae,Streptococcus pneumoniae and Streptococcus species. This 510(k) is for the addition of Clindamycin in the dilution range of 0.015-1ug/ml to the Sensititre HP MIC susceptibility plate for testing Streptococcus species. The approved primary "Indications for Use" and clinical significance of Clindamycin is for: Faculative Gram-Positive Fastidious Microorganisms: Streptococcus pyogenes Streptococcus agalactiae Streptococcus anginosus

Not Found

This FDA 510(k) clearance letter pertains to the Sensititre Haemophilus influenzae/Streptococcus pneumoniae Susceptibility Plates, specifically for the addition of Clindamycin for testing Streptococcus species. While the document indicates that studies were conducted to support the substantial equivalence of the device, it does not contain the detailed study results, acceptance criteria, or performance data.

The letter is a regulatory approval document confirming that the device is substantially equivalent to legally marketed predicate devices, based on information provided in the 510(k) submission. It refers to "indications for use stated in the enclosure," and the enclosure (page 2) details the specific indication for Clindamycin.

Therefore, I cannot provide the requested information from this document. To answer your questions, one would need access to the full 510(k) submission document, which would include the clinical and analytical study reports.

Ask a specific question about this device